Pages that link to "Item:Q3064270"
From MaRDI portal
The following pages link to A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents (Q3064270):
Displaying 11 items.
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
- A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate (Q1733138) (← links)
- Adaptive oncology Phase I trial design of drug combinations with drug-drug interaction modeling (Q1782097) (← links)
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials (Q2080762) (← links)
- A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering (Q2170396) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- A Bayesian approach to assessing the superiority of a dose combination (Q4389808) (← links)
- Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents (Q4967095) (← links)
- Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations (Q5041342) (← links)
- Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (Q5050425) (← links)
- A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations (Q5135528) (← links)
